Indian share markets ended higher ended higher as a surprise cut in the government’s borrowing programme for the next fiscal year boosted sentiment, with lenders such as the State Bank of India among top gainers. At the closing bell, the BSE Sensex finished higher by 108 points. While, the NSE Nifty finished up by 54 points. Meanwhile, the S&P BSE Midcap Index ended up by 1.1% while S&P BSE Small Cap Index ended up by 1.4%.
Sectoral indices ended the day on a mixed note with information technology stocks and automobile stocks leading the gainers. While, energy stocks and metal stocks ended the day in red.
Overseas, Asian stock markets finished broadly higher today with shares in Japan leading the region. The Nikkei 225is up 2.65% while China’s Shanghai Composite is up 1.05% and Hong Kong’s Hang Seng is up 0.79%. European markets are sharply higher today with shares in Germany leading the region. The DAX is up 1.96% while London’s FTSE 100 is up 1.83% and France’s CAC 40 is up 1.46%.
The rupee was trading at Rs 64.80 against the US$ in the afternoon session.
In the news from the pharma sector. As per an article in a leading financial daily, Glenmark Pharmaceuticals has received final nod from US health regulator for its Clobetasol Propionate spray. It used for treatment of moderate to severe plaque psoriasis in adults.
The product is generic version of Galderma Laboratories L P’s Clobex spray in the same strength.
This product will be manufactured at the Glenmark’s Baddi plant in Himachal Pradesh.
As per IQVIA sales data for the 12-month period ending January 2018, the Clobex spray, 0.05% market that includes brand and all available therapeutic equivalents achieved annual sales of approximately US$ 30.5 million.
The company’s portfolio consists of 131 products authorized for distribution in the US market and 63 ANDA’s pending approval with the USFDA.
